• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Investors pour $25M into telerad firm

Article

NightHawk Radiology Holdings, a provider of off-hour teleradiology services to U.S. facilities, has received a $25 million investment from Summit Partners, a private equity and venture capital firm. The teleradiology provider, based in Coeur D'Alene, ID,

NightHawk Radiology Holdings, a provider of off-hour teleradiology services to U.S. facilities, has received a $25 million investment from Summit Partners, a private equity and venture capital firm. The teleradiology provider, based in Coeur D'Alene, ID, employs U.S.-trained American Board of Radiology-certified physicians to provide preliminary radiological interpretations from a central reading facility in Sydney, Australia. The physicians electronically receive, read, and respond to the submitted radiology scans in a transcribed report sent to the attending physician. Staff read more than 1500 scans per night, providing service to more than 350 hospitals, radiology groups, and clinics.

Recent Videos
Emerging Research at SNMMI Examines 18F-flotufolastat in Managing Primary and Recurrent Prostate Cancer
Could Pluvicto Have a Role in Taxane-Naïve mCRPC?: An Interview with Oliver Sartor, MD
New SNMMI President Cathy Cutler, PhD, Discusses Current Challenges and Goals for Nuclear Medicine
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Fiber Optic RealShape (FORS) Technology Provide a Viable Alternative to X-Rays for Aortic Procedures?
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Related Content
© 2024 MJH Life Sciences

All rights reserved.